[go: up one dir, main page]

DK4043460T3 - Antiproliferationsforbindelser og anvendelser deraf - Google Patents

Antiproliferationsforbindelser og anvendelser deraf Download PDF

Info

Publication number
DK4043460T3
DK4043460T3 DK22161962.0T DK22161962T DK4043460T3 DK 4043460 T3 DK4043460 T3 DK 4043460T3 DK 22161962 T DK22161962 T DK 22161962T DK 4043460 T3 DK4043460 T3 DK 4043460T3
Authority
DK
Denmark
Prior art keywords
antiproliferative compounds
antiproliferative
compounds
Prior art date
Application number
DK22161962.0T
Other languages
English (en)
Inventor
Shashank Kulkarni
Henry Yu
Michael Clark
Guy Bemis
Michael Boyd
Kishan Chandupatla
Philip Collier
Hongbo Deng
Huijun Dong
Warren Dorsch
Russell R Hoover
Mac Arthur Johnson Jr
Marina Penney
Steven Ronkin
Darin Takemoto
Qing Tang
Nathan D Waal
Tiansheng Wang
David J Lauffer
Pan Li
Original Assignee
Merck Patent Gmbh
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Vertex Pharma filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK4043460T3 publication Critical patent/DK4043460T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/107Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • C07D491/113Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK22161962.0T 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf DK4043460T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661719P 2018-04-24 2018-04-24
EP19726792.5A EP3784666B1 (en) 2018-04-24 2019-04-23 Antiproliferation compounds and uses thereof

Publications (1)

Publication Number Publication Date
DK4043460T3 true DK4043460T3 (da) 2024-08-26

Family

ID=66655429

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19726792.5T DK3784666T3 (da) 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf
DK22161962.0T DK4043460T3 (da) 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19726792.5T DK3784666T3 (da) 2018-04-24 2019-04-23 Antiproliferationsforbindelser og anvendelser deraf

Country Status (27)

Country Link
US (4) US10815225B2 (da)
EP (2) EP3784666B1 (da)
JP (2) JP7304892B2 (da)
KR (1) KR102813581B1 (da)
CN (1) CN112236428B (da)
AR (1) AR114496A1 (da)
AU (1) AU2019261308B2 (da)
BR (1) BR112020020940A2 (da)
CA (1) CA3098335A1 (da)
CY (1) CY1125433T1 (da)
DK (2) DK3784666T3 (da)
ES (2) ES2987356T3 (da)
FI (1) FI4043460T3 (da)
HR (2) HRP20220710T1 (da)
HU (2) HUE067936T2 (da)
IL (2) IL301501B2 (da)
LT (1) LT3784666T (da)
MX (1) MX2020011089A (da)
PL (2) PL4043460T3 (da)
PT (2) PT3784666T (da)
RS (1) RS63281B1 (da)
SG (1) SG11202009500QA (da)
SI (1) SI3784666T1 (da)
SM (1) SMT202200308T1 (da)
TW (1) TWI813673B (da)
WO (1) WO2019209759A1 (da)
ZA (1) ZA202006071B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3784666T3 (da) 2018-04-24 2022-06-20 Merck Patent Gmbh Antiproliferationsforbindelser og anvendelser deraf
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020236834A1 (en) * 2019-05-20 2020-11-26 Seshadri Raju Modified z stents for iliac vein stenting
EP4285723A3 (en) 2019-12-20 2024-03-27 Bayer Aktiengesellschaft Substituted thiophene carboxamides, thiophene carboxylic acids and derivatives thereof
WO2024073502A1 (en) * 2022-09-28 2024-04-04 Accutar Biotechnology Inc. Heterocyclic compounds as e3 ligase inhibitors
WO2025223536A1 (zh) * 2024-04-26 2025-10-30 正大天晴药业集团股份有限公司 稠合双环化合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
DE19840028A1 (de) 1998-09-02 2000-03-09 Max Planck Gesellschaft Nucleinsäuremoleküle codierend Enzyme, die Fructosyltransferaseaktivität besitzen, und deren Verwendung
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DK1389617T3 (da) 2001-04-27 2007-05-07 Zenyaku Kogyo Kk Heterocyclisk forbindelse og antitumormiddel indeholdende denne som den aktive bestanddel
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
IL166718A0 (en) 2002-08-14 2006-01-15 Atugen Ag Further use of protein kinase n beta
NZ542475A (en) 2003-04-03 2009-04-30 Semafore Pharmaceuticals Inc PI-3 kinase inhibitor prodrugs
ATE546456T1 (de) 2003-05-30 2012-03-15 Gemin X Pharmaceuticals Canada Inc Triheterocyclische verbindungen, zusammensetzungen, und verfahren zur behandlung von krebs
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
KR101509440B1 (ko) 2005-05-12 2015-04-07 애브비 바하마스 리미티드 아폽토시스 촉진제
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
UA116188C2 (uk) 2005-10-07 2018-02-26 Екселіксіс, Інк. Інгібітори фосфатидилінозит-3-кінази і способи їх застосування
KR101467723B1 (ko) 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
PL2529621T3 (pl) 2006-09-22 2017-06-30 Pharmacyclics Llc Inhibitory kinazy tyrozynowej brutona
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
KR101737753B1 (ko) 2007-03-12 2017-05-18 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
US8394794B2 (en) 2007-03-23 2013-03-12 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
CN102026999B (zh) 2008-03-11 2014-03-05 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
AR076014A1 (es) 2009-04-02 2011-05-11 Sanofi Aventis Derivados de 3- (1,4) oxazepan -4-pirimidona
WO2011067219A1 (en) * 2009-12-04 2011-06-09 F. Hoffmann-La Roche Ag Diphenyl azepine derivatives as monoamine reuptake inhibitors
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20180118721A1 (en) 2015-02-13 2018-05-03 Merck Patent Gmbh Pyrimidine derivatives
DK3784666T3 (da) 2018-04-24 2022-06-20 Merck Patent Gmbh Antiproliferationsforbindelser og anvendelser deraf

Also Published As

Publication number Publication date
HRP20220710T1 (hr) 2022-07-22
DK3784666T3 (da) 2022-06-20
HUE058746T2 (hu) 2022-09-28
CN112236428A (zh) 2021-01-15
LT3784666T (lt) 2022-06-10
PT4043460T (pt) 2024-09-10
AU2019261308B2 (en) 2022-09-08
HUE067936T2 (hu) 2024-11-28
IL278142B2 (en) 2023-11-01
US11440907B1 (en) 2022-09-13
AR114496A1 (es) 2020-09-09
TW202012400A (zh) 2020-04-01
RS63281B1 (sr) 2022-06-30
IL278142A (en) 2020-11-30
EP3784666A1 (en) 2021-03-03
IL301501B2 (en) 2024-10-01
US20230150993A1 (en) 2023-05-18
ZA202006071B (en) 2024-01-31
CA3098335A1 (en) 2019-10-31
EP4043460A1 (en) 2022-08-17
PL3784666T3 (pl) 2022-07-18
CY1125433T1 (el) 2025-05-09
PT3784666T (pt) 2022-06-06
HRP20241163T1 (hr) 2024-11-22
SG11202009500QA (en) 2020-11-27
US12195453B2 (en) 2025-01-14
KR102813581B1 (ko) 2025-05-29
CN112236428B (zh) 2025-04-01
WO2019209759A1 (en) 2019-10-31
TWI813673B (zh) 2023-09-01
SI3784666T1 (sl) 2022-07-29
ES2919572T3 (es) 2022-07-27
JP2023101824A (ja) 2023-07-21
MX2020011089A (es) 2020-11-06
BR112020020940A2 (pt) 2021-03-02
PL4043460T3 (pl) 2024-10-28
SMT202200308T1 (it) 2022-09-14
EP3784666B1 (en) 2022-03-16
ES2987356T3 (es) 2024-11-14
IL301501A (en) 2023-05-01
JP2021522242A (ja) 2021-08-30
IL278142B1 (en) 2023-07-01
KR20210005151A (ko) 2021-01-13
FI4043460T3 (fi) 2025-05-09
IL301501B1 (en) 2024-06-01
AU2019261308A1 (en) 2020-10-22
EP4043460B1 (en) 2024-06-05
US10815225B2 (en) 2020-10-27
US20250188070A1 (en) 2025-06-12
JP7304892B2 (ja) 2023-07-07
US20190322658A1 (en) 2019-10-24

Similar Documents

Publication Publication Date Title
DK3877052T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3946464T3 (da) Forbindelser og konjugater deraf
IL282998A (en) Pyridazinone compounds and uses thereof
IL285461A (en) Processes and compounds
DK3784283T3 (da) Cannabidiopræparater og anvendelser deraf
DK3625263T3 (da) Anti-galectin- 9-antistoffer og anvendelser deraf
DK3383916T3 (da) Anti-CD73-antistoffer og anvendelser deraf
DK3365368T3 (da) Tgfbeta1-bindende immunoglobuliner og anvendelse deraf
DK3610005T3 (da) Peptidligase og anvendelse deraf
DK3658148T3 (da) Makrocykliske forbindelser og anvendelser deraf
IL278122B1 (en) Pteridinone compounds and uses thereof
DK3448386T3 (da) Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf
DK3596125T3 (da) Anti-PAR2-antistoffer og anvendelser deraf
DK3947375T3 (da) Imidazolonylquinolinforbindelser og terapeutiske anvendelser deraf
DK3784666T3 (da) Antiproliferationsforbindelser og anvendelser deraf
DK3402821T3 (da) Psma-bindende antistof og anvendelser deraf
DK3399978T3 (da) Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf
EP3893945A4 (en) CROMOGLYC ESTERS AND THEIR USES
DK3813946T3 (da) Rapamycin-analoger og anvendelser deraf
DK3672948T3 (da) Pyridinamin-pyridon- og pyrimidinamin-pyridonforbindelser
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf
DK3612579T3 (da) Pultrudat, fremstilling og anvendelse heraf
DK3653613T5 (da) 1,3-disubstitueret ketenforbindelse og anvendelse deraf
DK3743106T3 (da) Influenzavirusvacciner og anvendelser deraf
IL285118A (en) Compounds and uses thereof